Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

nextHERIZON: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment

NCT05311176 is registered in ClinicalTrials.gov with Imugene Limited as lead sponsor.

NCT NCT05311176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05311176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
nextHERIZON: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment
Lead sponsor
Imugene Limited
Phase
Phase 2
Overall status
Terminated
Start date
August 17, 2022
Completion date
April 4, 2024
Enrollment
7 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of stomach, gastric adenocarcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, stomach adenocarcinoma, stomach cancer